Journals / Türkiye Parazitoloji Dergisi / 2020 / Cilt: 44 - Sayı: 4

Antileishmanial Activity of New Synthesized Schiff and Mannich (Morpholine) Base Compounds

Sentezlenmiş Schiff ve Mannich (Morfolin) Bazı Bileşiklerinin Antileishmanial Aktiviteleri

Pages
216–220
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to the results, there is a need for further studies, such as in vivo experimental animal models and ex vivoLeishmania amastigote macrophage cultures for compounds showing antileishmanial effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Leishmaniasis is an important parasitic disease in many countries, including ours.
📊
Key Findings & Data:Compounds were diluted in the range of 20000-39 μg/mL.
💡
Conclusion & Impact:According to the results, there is a need for further studies, such as in vivo experimental animal models and ex vivoLeishmania amastigote macrophage cultures for compounds showing antileishmanial effects.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Leishmaniasis is an important parasitic disease in many countries, including ours. A variety of drugs are currently used for its treatment. However, certain side effects of these drugs, such as teratogenicity, hepatotoxicity and nephrotoxicity, have been reported in some patients. The goal of this research is to determine the antileishmanial effects of eight different previously synthesised compounds containing Schiff and Mannich bases (morpholine) against Leishmania infantum (L. infantum) promastigotes by the liquid microdilution method utilising alamarBlue.Methods:Compounds containing Schiff bases (a-d) and both Schiff bases and morpholine rings (e-h) were tested. Compounds were diluted in the range of 20000-39 μg/mL. L. infantum promastigotes were added to the wells, which were then incubated at 27 °C. The proliferation of Leishmania promastigotes was evaluated after 24, 48 and 72 hours.Results: In this study, compounds b, c and d (MIC values 156 μg/mL, 78 μg/mL and 156 μg/mL) were found to be effective against L. infantum promastigotes, whereas compound f (MIC >20000 μg/mL) was found to be more the most ineffective compound.Conclusion: These compounds may be potential drug candidates for the treatment of leishmaniasis. According to the results, there is a need for further studies, such as in vivo experimental animal models and ex vivoLeishmania amastigote macrophage cultures for compounds showing antileishmanial effects.

Özet

Amaç:Leishmaniasis, ülkemizin de dahil olmak üzere birçok ülkede önemli bir parazitik hastalıktır. Hastalığın tedavisinde birbirinden farklı çok sayıda ilaç kullanılmaktadır. Ancak, bazı hastalarda bu ilaçlara bağlı ortaya çıkan teratojenite, hepatotoksisite ve nefrotoksisite gibi birtakım yan etkiler bildirilmiştir. Bu araştırmanın amacı, alamar mavisi içeren sıvı mikrodilüsyon yöntemi ile Leishmania infantum (L. infantum) promastigotlarına karşı önceden sentezlenmiş [Schiff ve Mannich (morpholine) baz içeren] sekiz farklı bileşiğin antileishmanial aktivitesinin belirlenmesidir.Yöntemler:Çalışma kapsamında Schiff bazı içeren bileşikler (a-d) ile hem Schiff hem de morfolin halkası içeren bileşikler (e-h) test edilmiştir. Sentezlenen bileşikler 20000-39 μg/mL konsantrasyon aralığında olacak şekilde hazırlanmıştır. L. infantumpromastigotları kuyucuklara ilave edilerek 27 °C’de inkübe edilmiştir. L. infantum promastigotlarının üremesi 24., 48. ve 72. saatlerde değerlendirilmiştir. Bulgular: Bu çalışmada; b, c ve d bileşiklerinin (MİK değeri 156 μg/mL, 78 μg/mL ve 156 μg/mL) L. infantum promastigotlarına karşı daha etkili olduğu ve bileşik f ’nin ise (MİK >20000 μg/mL) en etkisiz bileşik olduğu bulunmuştur. Sonuç: Bu bileşikler leishmaniasisin tedavisindepotansiyel ilaç adayları olabilir. Bu çalışmanın sonuçları göstermektedir ki, in vitroantileishmanial etki gösteren bu bileşiklerin in vivo deneysel hayvan modelleri ve ex vivoLeishmania amastigot makrofaj kültürleri gibi daha ileri modellerle çalışılmasına ihtiyaç bulunmaktadır

🔖

Cite This Article

ÜNVER, Y., DİREKEL, Ş., AKDEMİR, C. (2022). Antileishmanial Activity of New Synthesized Schiff and Mannich (Morpholine) Base Compounds. Türkiye Parazitoloji Dergisi, Cilt: 44 - Sayı: 4, 216–220. https://ajindex.com/articles/629966

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Süleymanoğlu N, Ünver Y, Ustabaş R, Direkel Ş, Alpaslan G. Antileishmanial activity study and theoretical calculations for 4-amino-1,2,4-triazole derivatives. J Mol Struct 2017; 1144: 80-6
  2. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000Res 2017; 6: 750
  3. Markell EK, John DT, Krotoski VA. Markell and Voge’s Medical Parasitology. Philadelphia: WB Saunders; 1999.p.340-5
  4. Tchokouaha Yamthe LR, Appiah-Opong R, Tsouh Fokou PV, Tsabang N, Fekam Boyom F, Nyarko AK, et al. Marine Algae as Source of Novel Antileishmanial Drugs: A Review. Drugs 2017; 15: 323
  5. Corral MJ, González E, Cuquerella M, Alunda JM. Improvement of 96-well microplate assay for estimation of cell grow than dinhibition of leishmania with alamar blue. J Microbiol Methods 2013; 94: 111-6
  6. Doğan N, Bör O, Dinleyici EC, Töz SO, Özbel Y. Investigation of anti-leishmania seroprevalence by different serologic assays in children inhabiting in then or the western part of Turkey Mikrobiyol Bul 2008; 42: 103-11
  7. Armeli Minicante S, Michelet S, Bruno F, Castelli G, Vitale F, Sfriso A, et al. Bioactivity of phycocolloids against the mediterranean protozoan Leishmania infantum: An inceptive study. Sustainability 2016; 8: 1131
  8. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27: 305-18
  9. Dos Santos AO, Ueda-Nakamura T, Dias Filho BP, da Veiga Junior VF, Nakamura CV. Copaiba oil: An alternativeto development of new drugs against leishmaniasis. Evid Based Complement Alternat Med 2012; 2012: 898419
  10. Bekhit AA, Haimanot T, Hymete A. Evaluation of some 1H-pyrazole derivatives as a dual acting antimalarial and anti-leishmanial agents. Pak J Pharm Sci 2014; 27: 1767-73
  11. Özbilgin A, Çavuş İ, Yıldırım A, Kaya T, Ertabaklar H. Evaluation of in vitro and in vivo drug efficacy over leishmania tropica: a pilot study. Turkiye Parazitol Derg 2018; 42: 11-9.12. Özbilgin A, Çavuş İ, Kaya T, Yıldırım A, Harman M. Pentavalent antimonial bileşiklere dirençli vahşi leishmania izolatlarının leishmaniasis tedavisinde kullanılan ilaçlara karşı in vitro dirençlerinin karşılaştırılması. Turkiye Parazitol Derg 2020; 44: 12-6
  12. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366: 1561-77
  13. De Araújo MV, de Souza PS, de Queiroz AC, da Matta CB, Leite AB, da Silva AE, et al. Synthesis, leishmanicidal activity and theoretical evaluations of a series of sub